Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib plus Rituximab for MZL
NCT06478472Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Jun 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of orelabrutinib in marginal zone lymphoma (MZL), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Complete Response up to 36 months. Started Jun 2024; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT06478472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06478472.